Travere Therapeutics presents positive data on FILSPARI's effectiveness in treating kidney diseases

From GlobeNewswire: 2024-10-26 07:01:00

Travere Therapeutics presented new data at the American Society of Nephrology Kidney Week highlighting FILSPARI’s effectiveness in treating IgA nephropathy and focal segmental glomerulosclerosis. In the SPARTAN study, nearly 60% of patients achieved complete remission with FILSPARI as a first-line treatment. Results from the PROTECT study showed superior proteinuria reduction with FILSPARI compared to irbesartan, regardless of baseline levels. In the SPARTACUS study, data demonstrated FILSPARI’s efficacy in combination therapy. In the DUPLEX study, sparsentan showed rapid proteinuria reduction and kidney health benefits in genetic FSGS patients. Preliminary data from the EPPIK study in pediatric patients also showed promising results.



Read more at GlobeNewswire: Travere Therapeutics Presents Data Reinforcing Clinical